In patients with T2D who had been hospitalized for poorly controlled blood glucose, SGLT2 inhibitors nearly doubled the risk for falls, and combined use with GLP-1 RAs nearly tripled the risk.

Synthetic biology explained, future of synthetic biology, what is synthetic biology, creating life from DNA, synthetic life creation, synthetic biology techn…
Join us on Patreon! https://www.patreon.com/MichaelLustgartenPhDDiscount Links/Affiliates: Blood testing (where I get the majority of my labs): https://www.u…
Northwestern University engineers have developed a pacemaker so tiny that it can fit inside the tip of a syringe — and be non-invasively injected into the body.
Smaller than a single grain of rice, the pacemaker is paired with a small, soft, flexible, wireless, wearable device that mounts onto a patient’s chest to control pacing. When the wearable device detects an irregular heartbeat, it automatically shines a light pulse to activate the pacemaker. These short pulses— which penetrate through the patient’s skin, breastbone and muscles — control the pacing. #Repost
Although it can work with hearts of all sizes, the pacemaker is particularly well-suited to the tiny, fragile hearts of newborn babies with congenital heart defects.
Designed for patients who only need temporary pacing, the pacemaker simply dissolves after it’s no longer needed. All the pacemaker’s components are biocompatible, so they naturally dissolve into the body’s biofluids, bypassing the need for surgical extraction.
Four children have gained life-changing improvements in sight following treatment with a pioneering new genetic medicine through Moorfields Eye Hospital and UCL Institute of Ophthalmology.
The work was funded by the NIHR Research Professorship, Meira GTx and Moorfields Eye Charity.
The 4 children were born with a severe impairment to their sight due to a rare genetic deficiency that affects the ‘AIPL1’ gene. The defect causes the retinal cells to malfunction and die. Children affected are only able to distinguish between light and darkness. They are legally certified as blind from birth.
The new treatment is designed to enable the retinal cells to work better and to survive longer. The procedure, developed by UCL scientists, consists of injecting healthy copies of the gene into the retina through keyhole surgery. These copies are contained inside a harmless virus, so they can penetrate the retinal cells and replace the defective gene.
The condition is very rare, and the first children identified were from overseas. To mitigate any potential safety issues, the first 4 children received this novel therapy in only one eye.
The eye gene therapy was delivered via keyhole surgery at Great Ormond Street Hospital. The children were assessed in the NIHR Moorfields Clinical Research Facility, and the NIHR Moorfields Biomedical Research Centre provided infrastructure support for the research.
Complete the security check before continuing. This step verifies that you are not a bot, which helps to protect your account and prevent spam.
The potential role of vitamin D in preventing and treating colorectal cancer (CRC) has attracted growing research interest – especially as CRC rates are rising, particularly among younger adults. This isn’t a new area of study. Low vitamin D levels have long been linked to a higher risk of developing colorectal cancer.
One large study involving over 12,000 participants found that people with low blood levels of vitamin D had a 31 per cent greater risk of developing CRC compared to those with higher levels. Similarly, another study reported a 25 per cent lower CRC risk among individuals with high dietary vitamin D intake.
Data from the Nurses’ Health Study – a long-term investigation of American nurses – showed that women with the highest vitamin D intake had a 58 per cent lower risk of developing colorectal cancer compared to those with the lowest intake.